Pfizer Inc. (NYSE:PFE) – Jefferies Group issued their Q3 2016 earnings estimates for Pfizer in a research report issued on Thursday. Jefferies Group analyst J. Holford anticipates that the firm will post earnings of $0.63 per share for the quarter. Jefferies Group has a “Hold” rating and a $36.00 price objective on the stock.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same period in the previous year, the business earned $0.56 earnings per share. The firm’s revenue was up 10.9% on a year-over-year basis.
Other equities analysts also recently issued reports about the company. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target on the stock in a research note on Monday, June 27th. Deutsche Bank AG restated a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research note on Thursday, August 18th. Credit Suisse Group AG restated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research note on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, August 23rd. Finally, Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Eleven research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $38.59.
Pfizer (NYSE:PFE) opened at 32.66 on Friday. The stock has a market capitalization of $198.10 billion, a PE ratio of 28.95 and a beta of 0.86. Pfizer has a 52-week low of $28.25 and a 52-week high of $37.39. The company’s 50-day moving average price is $34.02 and its 200 day moving average price is $34.27.
Several hedge funds and other institutional investors have recently made changes to their positions in PFE. Nelson Roberts Investment Advisors LLC raised its position in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the period. Stelac Advisory Services LLC bought a new stake in Pfizer during the second quarter valued at $110,000. Tuttle Tactical Management LLC bought a new stake in Pfizer during the second quarter valued at $117,000. Gierl Augustine Investment Management Inc increased its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 205 shares in the last quarter. Finally, Catamount Wealth Management increased its stake in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 545 shares in the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.